Clinical trial THINK
A multinational, open-label, dose escalation Phase I/II study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Celyad |
| EudraCT Identifier | 2016-003312-12 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03018405 |
| Inclusion criteria | relapsed or refractory AML / MDS with R-IPSS ? 2 with failure to prior treatment/ not eligible for standard of care therapy |
| Last update |